Humana (HUM) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
22 Apr, 2026Opening remarks and agenda
Meeting opened by the Chairman, with thanks to stockholders and an overview of the meeting's electronic materials and rules of conduct.
Voting window opened for stockholders, with instructions for proxy and live voting.
Formal business included election of directors, auditor ratification, executive compensation advisory vote, stock incentive plan approval, and a shareholder proposal on golden parachutes.
Shareholder proposals
Proposal 5 requested shareholder approval for executive severance exceeding 2.99x salary plus bonus, citing long-term stock underperformance.
Proponent noted partial adoption of the proposal by the board and referenced similar support at other companies.
Overview of voting outcomes
All director nominees were elected.
Auditor ratification, executive compensation advisory vote, and the 2026 Stock Incentive Plan were approved.
The shareholder proposal on excessive golden parachutes was not approved.
Latest events from Humana
- Q2 2026 net income and revenues rose on Medicare and MaxHealth growth; guidance affirmed.HUM
Q2 202629 Jul 2026 - Q1 2025 net income and EPS surged; FY 2025 Adjusted EPS guidance reaffirmed at $16.25.HUM
Q1 20259 Jul 2026 - Revenue up 23.5% to $39.6B; Adjusted EPS $10.31; robust Medicare growth; higher benefit costs.HUM
Q1 202630 Apr 2026 - 2025 adjusted EPS reached $17.14; 2026 targets at least $9.00 EPS and 25% MA growth.HUM
Q4 202514 Apr 2026 - Margin targets, quality membership growth, and strategic acquisitions drive long-term outlook.HUM
Leerink Global Healthcare Conference 202610 Mar 2026 - Proxy covers director elections, executive pay, new stock plan, and ESG priorities.HUM
Proxy Filing6 Mar 2026 - Board recommends approval of all proposals except the golden parachute shareholder proposal.HUM
Proxy Filing6 Mar 2026 - Annual meeting covers director elections, compensation, new equity plan, and ESG progress.HUM
Proxy Filing6 Mar 2026 - Net income declined 29% as higher Medicare Advantage costs offset strong revenue growth.HUM
Q2 20242 Feb 2026